Return to search

Clearview Capital exits CMS

Clearview Capital has sold Scottsdale, Arizona-based CMS, a provider of of medication-assisted treatment for individuals afflicted with opioid use disorder.

Clearview Capital has sold Scottsdale, Arizona-based CMS, a provider of of medication-assisted treatment for individuals afflicted with opioid use disorder. No financial terms were disclosed. Houlihan Lokey and Alston & Bird LLP advised Clearview Capital and CMS on the deal.

PRESS RELEASE

STAMFORD, CT, DECEMBER 22, 2021 – Clearview Capital Fund III, L.P. (“Fund III”), an affiliate of Clearview Capital, L.P. (“Clearview Capital”), today announced the sale of its majority interest in Community Medical Acquisition Corp. and its subsidiaries (collectively “CMS” or the ”Company”). The transaction closed on December 15, 2021.

Founded in 1983 and headquartered in Scottsdale, Arizona, CMS is a rapidly growing provider of medication-assisted treatment (“MAT”) for individuals afflicted with opioid use disorder (“OUD”). Led by CEO, Nick Stavros, the Company currently operates from more than 50 clinics across nine states. CMS has been at the forefront of expanding access to treatment services, including opening the nation’s first 24-hour Opioid Treatment on Demand (“OTOD”) center in Phoenix in 2017.

“CMS is one of the most mission-driven companies we have had the pleasure to work with,” remarked Matthew Blevins, Managing Partner of Clearview Capital. “The Company’s employees are on the front line of our country’s ongoing battle against the opioid epidemic, which has been exacerbated by the pandemic. Since Fund III’s initial investment in 2018, the Company closed and integrated four add-on acquisitions; opened more than 20 new clinics; entered five new states; and increased the number of patients it serves daily from approximately 3,000 to more than 18,000. We couldn’t be prouder of our partnership with CMS’s management team, and we wish them continued success.”

“Clearview Capital was the perfect provider of our first institutional capital,” commented Mr. Stavros. “The Clearview team understood and supported our vision for the Company and provided the necessary resources to allow us to rapidly expand our treatment services and geographic footprint, and the mutual trust established between us and Clearview as our capital partner was paramount to our success. Moreover, the Clearview team’s knowledge of and prior investments in the behavioral health industry allowed us to immediately focus on executing our growth strategy. We could not have succeeded in accomplishing our mission over the last three years without Clearview’s support and will forever be grateful that we were able to partner with them as our first institutional capital partner.”

“The sale of CMS marks our sixth successful exit from Fund III,” commented Calvin Neider, Managing Partner and Co-Founder of Clearview Capital. “We have thoroughly enjoyed our partnership with the CMS leadership team and wish all the best for the Company as it moves to its next phase of growth.”

CMS and Clearview Capital were advised by Houlihan Lokey and Alston & Bird LLP.

Fund III, a $325 million vehicle raised in 2013, invested in CMS in March 2018.

About Community Medical Services
Community Medical Services is a CARF-accredited substance use disorder treatment program, providing outpatient medication-assisted treatment via medication, counseling, and community-based services. The Company offers treatment from more than 50 clinics across nine states. For more information, please visit www.communitymedicalservices.org.